©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Identification of a Variable Region within the Cytoplasmic Tail of the IL-2 Receptor Chain That Is Required for Growth Signal Transduction (*)

(Received for publication, June 13, 1995; and in revised form, July 18, 1995)

Kathleen D. Liu (1)(§) Stephen Y. Lai (1)(§) Mark A. Goldsmith (1) (2) Warner C. Greene (1) (2) (3)(¶)

From the  (1)Gladstone Institute of Virology and Immunology, Departments of (2)Medicine and (3)Microbiology and Immunology, School of Medicine, University of California, San Francisco, California 94141

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Interleukin-2 (IL-2) regulates numerous biological events, including T lymphocyte proliferation. Interleukin-2 receptor (IL-2R)-mediated signaling is triggered by ligand-induced heterodimerization of the IL-2Rbeta and (c) subunits, which results in the activation of signaling intermediates that are associated with either IL-2Rbeta or (c). Previous mutagenesis studies of the IL-2Rbeta cytoplasmic tail demonstrated that the partially conserved box 1 and box 2 motifs and specific tyrosine residues are critical for growth signaling. By deletion and alanine scanning mutagenesis, another set of residues that are critical for IL-2R-mediated signaling has now been identified. These residues lie within the divergent 35-amino acid ``spacer'' region separating box 1 and box 2. The role of this receptor subregion in early phases of IL-2R signaling was evaluated using BA/F3 stable cell lines expressing three functionally impaired mutants from this region. All three cell lines displayed substantially diminished growth responsiveness to IL-2. Receptor-mediated STAT factor activation, IL-2Rbeta phosphorylation, and Janus kinase activation were also markedly impaired. These findings indicate that this variable spacer region, which we have termed the V-box, is essential for the initiation of IL-2R-mediated signal transduction.


INTRODUCTION

The interleukin-2 receptor (IL-2R) (^1)complex exists in two functional forms: a high affinity heterotrimer comprising the IL-2Ralpha, IL-2Rbeta, and (c) subunits, as well as an intermediate affinity heterodimer containing the IL-2Rbeta and (c) chains. In T lymphocytes, binding of IL-2 to either form of the receptor activates an intracellular signaling cascade that culminates in cellular proliferation(1, 2) . The primary role of the IL-2Ralpha subunit is to confer high affinity binding of the ligand to the receptor complex(3, 4) . Consistent with this concept, the cytoplasmic tail of IL-2Ralpha is only 13 amino acids long (5, 6, 7) and no known signaling intermediates associate with this region. Instead, intracellular signal transduction results from ligand-induced heterodimerization of the IL-2Rbeta and (c) subunits, which have cytoplasmic tails of 385 and 86 amino acids, respectively.

Heterodimerization of these receptor chains results in the concurrent activation of signaling intermediates (8, 9, 10) , (^2)some of which are preassociated with either IL-2Rbeta or (c). Specifically, two members of the Janus family of tyrosine kinases, JAK1 and JAK3, are bound to the cytoplasmic regions of the IL-2Rbeta and (c) chains, respectively, in the absence of IL-2(11, 12, 13) . These tyrosine kinases become enzymatically activated following ligand binding, perhaps by cross-phosphorylation. However, the precise molecular details of this inductive event remain unclear. The JAK kinases in turn are thought to activate members of the STAT family of transcription factors (``signal transducers and activators of transcription''). Upon phosphorylation, the STAT factors dimerize and translocate to the nucleus, where they activate the transcription of specific target genes (reviewed in (14) ). In the IL-2R system, the activation of STAT5 has recently been demonstrated by a number of laboratories(15, 16, 17) , and in some cases, the activation of STAT1 and STAT3 has also been observed(16, 18) .

The IL-2Rbeta and (c) chains are both members of the cytokine receptor superfamily(19) . Receptors in this family share two extracellular motifs, a set of four cysteines with canonical spacing and a WSXWS sequence. Moreover, these proteins are also characterized by two small, partially conserved, intracellular regions called the box 1 and 2 motifs(20, 21) . These motifs are separated by a region often called the ``spacer,'' which varies in length from 13 to 49 amino acids in the various cytokine superfamily members.

Early mutagenesis studies of IL-2Rbeta focused on large deletions within the cytoplasmic tail. Analysis of the IL-2Rbeta SD mutant, which lacks residues 266-323, revealed that amino acids located within and surrounding the box 2 motif of IL-2Rbeta are critical for growth signaling(21) . More refined structure-function studies of the cytoplasmic tail of IL-2Rbeta have demonstrated that both the proximal box 1 and box 2 motifs, as well as specific tyrosine residues in the distal receptor tail, play a critical role in IL-2R-mediated growth signaling(1, 22) . Deletion of either box 1 or box 2 of IL-2Rbeta completely abrogated IL-2-induced proliferation. However, alanine scanning mutagenesis unexpectedly revealed that only two residues within boxes 1 and 2 contributed side chains critical for such signaling. These amino acids are Asp-258 in the box 1 motif (1) and Leu-299 in the box 2 motif(1, 23) . Interestingly, Asp-258 is poorly conserved in the box 1 elements of other cytokine superfamily members. This finding raised the possibility that variable rather than conserved residues might play a central role in growth signaling through the IL-2R complex. This hypothesis was attractive because it could help explain the specificity of signaling exhibited by various cytokine superfamily members despite the presence of partially conserved motifs. Accordingly, we have now investigated the nonconserved 35-residue spacer region separating Asp-258 in the distal portion of box 1 and Leu-299 in the proximal part of box 2. Since this spacer region is highly variable in amino acid composition in different cytokine receptor members, the term variable (V) box will be used to refer to it.


EXPERIMENTAL PROCEDURES

Cell Lines and Antibodies

BA/F3 is an IL-3-dependent murine pro-B cell line described previously (24) and generously provided by Dr. Gordon Mills. These cells were routinely maintained in RPMI 1640 supplemented with 10% fetal calf serum, antibiotics, 0.05 M beta-mercaptoethanol, and 10% WEHI supernatant as a source of IL-3. The COS-7 monkey kidney cell line (ATCC) was maintained in Iscove's medium supplemented with 10% fetal calf serum, 2 mM glutamine, and antibiotics. Recombinant human IL-2 was the gift of the Chiron Corp (Emeryville, CA). The anti-IL-2Rbeta monoclonal antibody 561 was a generous gift from Dr. Rich Robb. Polyclonal antibodies specific for JAK1 and JAK3 and a mouse monoclonal antibody to phosphotyrosine (4G10) were obtained from Upstate Biotechnology (Lake Placid, NY). Control murine IgG2a UPC10 monoclonal antibody was obtained from Cappel (Durham, NC). Chemiluminescent detection of blotted proteins was performed using an ECL kit (Amersham Corp.) according to the manufacturer's instructions.

Plasmid Construction and Mutagenesis

The pCMV4Neo vector was kindly provided by Dr. Mark Feinberg and has been described previously(1) . All deletion and substitution mutations within the IL-2Rbeta V-box were prepared using specific oligonucleotide primers and the polymerase chain reaction. The resultant mutants were confirmed by automated DNA sequencing (Applied Biosystems, Foster City, CA). To verify that the constructs expressed IL-2Rbeta chains of appropriate lengths, the constructs were transfected into COS-7 cells using Lipofectamine (Life Technologies, Inc.) according to the manufacturer's instructions. Two days post-transfection, the cells were lysed in 1% Nonidet P-40 (Calbiochem), 150 mM sodium chloride, 20 mM Tris-HCl, pH 8.0, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride (Boehringer Mannheim), 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 µg/ml pepstatin A. An aliquot of the lysate was subjected to SDS-PAGE, followed by immunoblotting with the anti-IL2Rbeta antibody 561.

Transient Transfection Assay of IL-2-induced Proliferation

Transient assays of IL-2-induced proliferation were performed in BA/F3 cells as described previously(1) . Thymidine (DuPont NEN) incorporation was measured on days 7-14 following transfection.

Establishment and Characterization of Cell Lines Stably Expressing IL-2Rbeta V-box Mutants

Stable cell lines were established by insertion of the relevant cDNAs into the pCMV4Neo expression plasmid followed by electroporation of BA/F3 cells. One day post-transfection, cells were suspended in standard BA/F3 medium supplemented with 1 mg/ml G418 (Life Technologies, Inc.). Cells were then grown in bulk culture for 5-6 days, and single clones isolated by limiting dilution. The number of mutant receptors expressed at the surface of the resultant cell lines was determined in I-IL-2 (DuPont NEN) binding assays performed as described previously(25) . Proliferative responses to IL-2 were assessed in these stable cell lines by measuring [^3H]thymidine incorporation 24 and 48 h after the addition of ligand. Studies of IL-2Rbeta tyrosine phosphorylation were performed as described previously(22) . In brief, 10^8 cells were washed twice in calcium- and magnesium-free PBS, and surface-bound growth factors from the tissue culture media were removed by incubation of the cells for 1 min in 10 mM sodium citrate, 140 mM sodium chloride. The cells were then resuspended in RPMI 1640 supplemented with 1% bovine serum albumin (Fraction V, Sigma) at a density of 1 times 10^6/ml. Cells were incubated for 4 h at 37 °C, harvested by centrifugation, and resuspended at a density of 10 times 10^6 cells/ml. The cells were split into two aliquots; one half was stimulated with IL-2 (10 nM final concentration) for 10 min at 37 °C, while the other was incubated in media in the absence of any growth factors. After stimulation, the cells were lysed 1% Nonidet P-40, 150 mM sodium chloride, 20 mM Tris-HCl, pH 8.0, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl fluoride, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 1 µg/ml pepstatin A. The anti-IL-2Rbeta monoclonal antibody 561 was used at a concentration of 2 µg/ml to immunoprecipitate the IL-2Rbeta chain, and antibody complexes were collected on protein A-Sepharose (Boehringer Mannheim). Immunoprecipitates were subjected to SDS-PAGE and subsequent immunoblotting with the antiphosphotyrosine monoclonal antibody 4G10.

STAT Induction

For each condition, 10^8 BA/F3 cells were stripped and starved as described above. The cells were subsequently stimulated with either IL-2 (10 nM final concentration) or IL-3 (10% WEHI 3B supernatant). Following stimulation, nuclear extracts were prepared according to the method described in (26) in the presence of 1 mM NaVO(4) and a protease mixture composed of the following inhibitors: 0.5 mg/ml antipain, 0.5 mg/ml aprotinin, 0.75 mg/ml bestatin, 0.5 mg/ml leupeptin, 0.05 mg/ml pepstatin A, 1.4 mg/ml phosphoramidon, and 0.5 mg/ml soybean trypsin inhibitor. Electrophoretic mobility shift assays (EMSA) were performed as described(17) .

JAK1 and JAK3 Phosphorylation

Studies of JAK1 and JAK3 phosphorylation in BA/F3 stable cell lines were performed in the same manner as the studies of IL-2Rbeta phosphorylation, except that 10^8 cells were used per condition, and the lysates were subjected to immunoprecipitation with polyclonal antibodies specific for JAK1 and JAK3. In some cases, the blots were stripped according to the manufacturer's instructions and reprobed with the anti-JAK1 or anti-JAK3 antibodies.


RESULTS

Replacement or Deletion of the IL-2Rbeta V-box Abrogates IL-2-mediated Growth Signaling

To assess the functional role of the IL-2Rbeta V-box in IL-2R-mediated growth signaling, a mutant IL-2Rbeta was created in which this 35-residue region was deleted and replaced with a single methionine residue. In addition, to test the hypothesis that this V-box region could be functionally complemented by an analogous domain from a different cytokine superfamily member, a chimeric IL-2Rbeta chain was prepared in which the native V-box was replaced with the corresponding region from the (c) receptor chain. The signaling function of each of these mutants was assessed in a transient proliferation assay(1) . In this assay, mutant IL-2Rbeta chains are transiently transfected into BA/F3, a (c)-expressing murine pro-B cell line. Growth selection in IL-2 permits the distinction between functional and nonfunctional forms of the IL-2Rbeta receptor. This assay appears to be more sensitive to small decrements in function than conventional stable proliferation assays. Both of these mutants failed to display any detectable function in this assay, suggesting that the removal or replacement of the V-box markedly impaired effective growth signaling (Fig. 1A).


Figure 1: Substitution and deletion analysis of the IL-2Rbeta V-box. A, mutant IL-2Rbeta chains were screened for proliferation function in a transient transfection assay. [^3H]Thymidine incorporation (shown in counts/min) was measured on days 7-14 post transfection. betaWT, wild-type IL-2Rbeta; betaDeltaV, IL-2Rbeta, deleted of residues 261-295 and replaced with a single methionine residue; beta:v, IL-2Rbeta, deleted of residues 261-293 and replaced with residues 284-318 from the (c) receptor chain; betaDelta261-269, IL-2Rbeta deleted of residues 261-269; betaDelta279-289, IL-2Rbeta deleted of residues 279-289; betaDelta290-294, IL-2Rbeta deleted of residues 290-294. B, IL-2Rbeta mutants were transfected into COS-7 cells to demonstrate that IL-2Rbeta chains of appropriate lengths are synthesized. Cell lysates were subjected to SDS-PAGE, followed by immunoblotting with an anti-IL-2Rbeta antibody, 561. The mutants analyzed are described in panelA.



To further define V-box sequences needed for growth signaling, a series of smaller deletion mutants was prepared and analyzed. Each of these mutants encoded a IL-2Rbeta chain lacking 5-10 amino acids within the V-box. Two of the mutants (IL-2RbetaDelta261-269 and IL-2RbetaDelta279-289) failed to proliferate in the transient proliferation assay (Fig. 1A), while a third mutant, corresponding to the most C-terminal deletion, IL-2RbetaDelta290-294, proliferated in response to IL-2. Expression studies in COS-7 cells confirmed that each of these various V-box mutants was synthesized (Fig. 1B), indicating that the observed lack of function observed was not due to a lack of expression. Together, these results suggest that the IL-2Rbeta V-box plays an important role in growth signaling by the IL-2R complex and that this function cannot be simply reconstituted by substitution of a V-box from another cytokine superfamily receptor member.

Alanine Scanning Mutagenesis Identifies Several Specific Residues Within the V-box That Are Critical For Growth Signaling

To delineate specific amino acids within the IL-2Rbeta V-box that participate in growth signaling, alanine scanning mutagenesis of this region was performed. Glycine, alanine, and valine residues were replaced with arginine residues, while all other amino acids were substituted with alanine. One to three contiguous amino acids were mutated in each construct. The effects of these substitution mutations in the transient proliferation assay are shown in Fig. 2A. Three of these point mutants, IL-2Rbeta261-263A, IL-2Rbeta270A 271-2R, and IL-2Rbeta278-280A, displayed essentially no proliferation in the transient assay. Expression studies in COS-7 cells confirmed that all three of these constructs encoded appropriately sized IL-2Rbeta molecules (Fig. 2B). In contrast, a fourth V-box mutant, IL-2Rbeta264-266A, displayed completely normal proliferation in response to IL-2. The IL-2Rbeta264-266A mutant was chosen as an internal control for more detailed study in stable cell lines, as described below. These studies thus indicated that the IL-2Rbeta V-box contains both essential and nonessential amino acids for growth signaling.


Figure 2: Alanine scanning mutagenesis of the IL-2Rbeta V-box. A, schematic of IL-2Rbeta V-box mutants that were constructed. Mutants were assayed for function in the transient proliferation assay as described in Fig. 1. Results are summarized as the mean peak proliferative response obtained in a representative assay and the standard error (S.E.) of triplicate determinations. The peak incorporation was normalized by expressing the peak incorporation as a percentage of the peak incorporation obtained with a wild-type IL-2Rbeta transfectant in each assay. B, expression study in COS-7 cells. The experiment was performed as described in Fig. 1, and the mutants are described above.



Establishment of BA/F3 Stable Cell Lines Expressing Mutant IL-2Rbeta Chains

In order to define more precisely the biochemical nature of growth signal disruption with the V-box mutations, BA/F3 cell lines stably expressing the V-box mutants IL-2Rbeta261-263A, IL-2Rbeta270A 271-2R, and IL-2Rbeta278-280A were developed. As a positive control, a cell line expressing the IL-2Rbeta264-266A V-box mutant (which displayed a wild-type proliferation phenotype) was also prepared. Scatchard analyses of I-IL-2 binding data demonstrated that each of these mutants was expressed at the cell surface and participated normally in the formation of intermediate affinity receptor complexes with the (c) chain (Fig. 3). Because of its comparable levels of surface receptor expression, the cell line expressing the functional IL-2Rbeta264-266A mutant served as a useful control for comparison with the nonfunctional V-box mutants.


Figure 3: Surface expression of nonfunctional IL-2Rbeta V-box mutants. BA/F3 stable cell lines encoding nonfunctional IL-2Rbeta V-box mutants were developed by transfection. As a positive control, a cell line expressing a V-box mutation that had no effect in the transient proliferation assay, IL-2Rbeta264-266A, was developed as well. Equilibrium (Scatchard) binding studies were performed using -I-IL-2 to determine expression and ligand binding characteristics of IL-2Rbeta/(c) receptor complexes.



IL-2R-mediated growth signaling was first assessed in these stable cell lines by measuring [^3H]thymidine incorporation in response to varying doses of IL-2. The IL-2Rbeta261-263A, IL-2Rbeta270A 272-2R, and IL-2Rbeta278-280A mutations all displayed markedly reduced responsiveness to IL-2 in the assay. As expected, the IL-2Rbeta264-266A mutant proliferated normally (Fig. 4). The IL-2Rbeta270A 271-272R mutant conferred the smallest shift in the dose-response curve, while the IL-2Rbeta278-280A mutant produced a more marked shift in response. The IL-2Rbeta261-263A mutant was essentially unresponsive to IL-2, even at very high doses. Hence, these data confirmed the results obtained with the transient proliferation assay and revealed more subtle differences between these three mutants.


Figure 4: Dose-response curves of nonfunctional IL-2Rbeta V-box mutants. Proliferative responses to IL-2 were assessed in these cell lines by measuring [^3H]thymidine incorporation 24 h after the addition of ligand. bullet, IL-2Rbeta wild-type; circle, IL-2Rbeta261-263A; times, IL-2Rbeta264-266A; , IL-2Rbeta270A 271-2R; , IL-2Rbeta278-280A.



V-box Mutants Fail to Activate STAT Factors

Recently, a number of STAT factors have been implicated in IL-2R signaling (15, 16, 17, 18) . Moreover, activation of one or more of these factors may play a role in proliferation signaling by the IL-2R complex, since many mutations in the receptor chains that abrogate STAT induction affect proliferation as well. (^3)Consequently, the V-box mutants described above were evaluated by EMSA for abnormalities in STAT induction. The STAT factor induced by IL-2 in the BA/F3 cell line was identified as STAT5, by supershifting of the STAT/DNA complex with an anti-STAT5 antibody (data not shown). As shown in Fig. 5, activation of STAT5 was detectable but markedly diminished in the cell lines expressing the IL-2Rbeta270A 271-2R and IL-2Rbeta278-280A mutants (lanes9 and 12), as compared to the receptor-matched control cell line. STAT activation was undetectable in the cell line expressing the IL-2Rbeta261-263A mutant (lane3). Despite these differences in STAT DNA binding activity, all of the nuclear extracts contained equivalent amounts of SP1 binding activity, as demonstrated by EMSA (data not shown), indicating that the diminished STAT factor detection in the V-box mutant cell lines was not due to inadvertent degradation of nuclear proteins during extract preparation. Thus, STAT activation is significantly decreased in the BA/F3 stable cell lines expressing two of the three V-box mutants (IL-2Rbeta270A 271-2R and IL-2Rbeta278-280A) and is undetectable in the third cell line (IL-2Rbeta261-263A).


Figure 5: STAT5 induction in BA/F3 stable transfectants expressing various IL-2Rbeta V-box mutations. Stable cell lines were stimulated with IL-2, IL-3, or no cytokine for 10 min. Following stimulation, nuclear extracts were prepared and subjected to EMSA using a F(c)RI probe. Lanes 1-3, IL-2Rbeta261-263A; lanes4-6, IL-2Rbeta264-266A; lanes 7-9, IL-2Rbeta270A 271-2R; lanes 10-12, IL-2Rbeta278-280A. Cells were stimulated with 10% WEHI 3B supernatant as a source of IL-3 (3), no cytokine(-), or 10 nM recombinant human IL-2 (2).



V-box Mutations Abrogate IL-2Rbeta Tyrosine Phosphorylation following IL-2 Binding

Studies were next performed to assess the effects of these V-box mutations on early IL-2R-mediated signaling events. STAT factors are thought to interact with specific phosphotyrosine residues within cytoplasmic receptor tails through SH2-mediated interactions(14) . Moreover, the rapid tyrosine phosphorylation of the IL-2Rbeta chain has been shown to be critical for effective growth signaling(22, 27, 28, 29, 30) . Therefore, it was of interest to determine whether or not IL-2Rbeta chain tyrosines were phosphorylated in cell lines stably expressing the various V-box mutants. In all three cases, IL-2Rbeta tyrosine phosphorylation was markedly reduced, as compared with the functional receptor-matched control cell line (Fig. 6, lanes4, 6, 8, and 10). The IL-2Rbeta270A 271-272R mutant displayed the highest level of IL-2Rbeta phosphorylation, consistent with its moderately shifted dose-response curve for proliferation. In contrast, tyrosine phosphorylation of IL-2Rbeta was undetectable in stable cell lines expressing either the IL-2Rbeta261-263A mutant or the IL-2Rbeta278-280A mutant.


Figure 6: Tyrosine phosphorylation of IL-2Rbeta in stable cell lines expressing IL-2Rbeta V-box mutations. Following IL-2 stimulation of the BA/F3 stable cell lines, the IL-2Rbeta chain was immunoprecipitated with an anti-IL2Rbeta monoclonal antibody, subjected to SDS-PAGE, and immunoblotted with an antiphosphotyrosine antibody. Lanes1 and 2, wild-type IL-2Rbeta; lanes3 and 4, IL-2Rbeta261-263A; lanes5 and 6, IL-2Rbeta264-266A; lanes7 and 8, IL-2Rbeta270A 271-2R; lanes9 and 10, IL-2Rbeta278-280A. Cells were stimulated with 10 nM recombinant human IL-2 (+) or incubated in the absence of cytokine(-) for 10 min.



V-box Mutations Abrogate JAK1 and JAK3 Induction

Having observed impaired STAT activation and reduced tyrosine phosphorylation of the IL-2Rbeta chain, the effects of these V-box mutations on an even earlier step in the signaling pathway, JAK activation, were investigated. Following the addition of IL-2, the JAK1 and JAK3 kinases undergo tyrosine phosphorylation within 5 min(31, 32) . This phosphorylation correlates with enzymatic activation of the Janus kinases in vitro.(31, 32) . Following IL-2 stimulation of the mutant V-box cell lines, tyrosine phosphorylation of JAK1 and JAK3 was assessed by serial immunoprecipitation and immunoblotting with an antiphosphotyrosine antibody. In all three of the nonfunctional V-box mutant cell lines assessed, IL-2-induced phosphorylation of JAK1 and JAK3 was undetectable (Fig. 7, A and B, respectively: lanes2, 4, 6, and 8). Hence, these IL-2Rbeta V-box mutations compromise one of the earliest signaling events mediated through the IL-2R complex.


Figure 7: JAK1 and JAK3 phosphorylation in stable cell lines encoding nonfunctional IL-2Rbeta V-box mutants. Following stimulation of the stable cell lines described in Fig. 3, JAK1 and JAK3 were serially immunoprecipitated and immunoblotted with an antiphosphotyrosine antibody to assess kinase induction. A, immunoprecipitations performed with an anti-JAK1 antibody. B, an anti-JAK3 antibody was used. In both cases, lanes1 and 2, IL-2Rbeta261-263A; lanes3 and 4, IL-2Rbeta264-266A; lanes5 and 6, IL-2Rbeta270A 271-2R; lanes7 and 8, IL-2Rbeta278-280A. Cells were stimulated with IL-2 (+) or incubated in the absence of cytokine(-) for 10 min.




DISCUSSION

Previous work from this and other laboratories has demonstrated that membrane-proximal regions of the cytoplasmic tail of IL-2Rbeta are critical for signaling by the IL-2R complex (for a review, see (33) ). Surprisingly, only a single residue in each of the box 1 and box 2 appears essential for growth signaling. Furthermore, the critical residue within the box 1 motif (Asp-258) is not well conserved among other cytokine receptor superfamily members. This result led us to consider the hypothesis that variable amino acids, rather than conserved residues, play an important role in signaling by IL-2Rbeta. Therefore, we focused on the spacer region positioned between the box 1 and box 2 motifs that contains predominantly nonconserved amino acids. Previous work had suggested that this region, which we have termed the V-box, plays a role in IL-2R-mediated growth signaling. The single critical residues identified in the box 1 and box 2 motifs directly flank the intervening V-box, i.e. Asp-258 is positioned at the C-terminal end of box 1, whereas Leu-299 is at the N-terminal end of box 2. Therefore, these motifs might serve to expose the critical intervening variable region, which could function as a binding platform for one or more signaling intermediates.

The mutagenesis approaches presented in this paper further support the hypothesis that the IL-2Rbeta V-box contains elements critical for growth signaling. A gross deletion of this region completely abrogated function in a transient assay of receptor function. Furthermore, a mutant in which the IL-2Rbeta V-box was replaced with an analogous portion of the (c) receptor also failed to support growth signaling. This result suggested that V-box elements are not readily interchangeable, although additional experimentation is required to prove the generality of this observation. It should be noted that the analogous region for substitution was defined on the basis of sequence homology, not function, and these artificial sequence boundaries might in fact interrupt functional domains. Thus, replacement of only the V-box region of this domain could result in a hybrid domain that cannot support growth signaling.

Finer mutagenesis studies, including alanine scanning of the IL-2Rbeta V-box region, identified a number of residues that are important for growth signaling in the transient proliferation assay. Many of these critical amino acids do not have side chains that can be phosphorylated or covalently modified in another way following ligand binding. Consequently, it seems unlikely that this region serves as an inducible binding site for a signaling intermediate; rather, this V-box region might serve as a constitutive docking site for one or more signaling molecules. Of note, replacement of Trp-277 with alanine does not affect receptor function. Previous mutagenesis studies had demonstrated that whereas a W277G mutation results in impaired IL-2Rbeta function(1) , a W277R mutation does not affect signaling by the receptor complex(34) . Consequently, Trp-277 may play an important role in the secondary or tertiary structure of this region, rather than contributing a specific side chain that participates directly in receptor-signaling intermediate interactions.

In studies designed to dissect where the V-box mutations exert their inhibitory effects within the signaling cascade, we examined a relatively distal effect of ligand-induced signaling, STAT activation. In the IL-2R system, mutants that display impaired STAT activation also fail to proliferate normally in response to IL-2, suggesting that STAT factors may play a role in growth signaling. In the stable cell lines expressing various V-box mutants, STAT activation is only barely detectable in the cell lines expressing IL-2Rbeta270A 271-2R or IL-2Rbeta278-280A and is undetectable in the cell line expressing IL-2Rbeta261-263A. Consequently, the V-box mutations must affect a signaling step proximal to STAT factor activation but distal to ligand binding.

Subsequent studies focused on earlier steps in the signaling cascade, in order to define more precisely the contribution of these critical V-box residues to IL-2R-mediated signaling. Phosphorylation of IL-2Rbeta tyrosines is thought to allow additional signaling intermediates to be recruited into the activated receptor complex, probably through SH2-mediated interactions. This phosphorylation is rapid and may contribute to effective growth signaling(22) . Since STAT activation is likewise thought to depend upon receptor-based phosphotyrosine residues, the integrity of IL-2Rbeta tyrosine phosphorylation was examined in these mutant cell lines. Importantly, ligand-induced tyrosine phosphorylation of IL-2Rbeta was inhibited in cell lines expressing each of the three nonfunctional V-box mutant receptors. Notably, a minor degree of IL-2Rbeta phosphorylation was detected in the IL-2Rbeta270A 271-2R line, but phosphorylation was undetectable in the IL-2Rbeta278-280A cell line. In contrast, as discussed above, a small degree of STAT activation was detectable in both the IL-2Rbeta270A 271-2R and IL-2Rbeta278-280A cell lines. These results may simply reflect a small difference in sensitivity of these two assays, with the gel shift analysis of STAT activation being the more sensitive of the two. Nonetheless, in both cases, IL-2Rbeta phosphorylation and STAT activation are minimal, as compared to the receptor-matched positive control cell line.

The diminution of IL-2Rbeta phosphorylation was particularly intriguing because it suggested that membrane-proximal mutations can affect signaling events occurring at more distal sites within the IL-2Rbeta chain. Moreover, this result suggests that these mutations affect an early signaling event known to be important for a full mitogenic response. The V-box therefore might be critical for the association of the cytoplasmic receptor tail with either a kinase that phosphorylates the IL-2Rbeta tail directly or a protein that activates such a kinase. In the erythropoietin receptor system, Aoki and co-workers (35) have recently shown that the association of JAK2 with the erythropoietin receptor is abrogated when a tryptophan residue within the V-box of this receptor is mutated to arginine. This suggests that the V-box of the erythropoietin receptor is also critical for the association of JAKs, although in the IL-2 system the association of these kinases appears to be constitutive rather than induced by ligand binding (11, 12, 13) .

In studies of JAK activation, neither JAK1 nor JAK3 was induced in any of the three nonfunctional V-box mutants studied, as measured by tyrosine phosphorylation. Others have mapped the JAK1 binding site on IL-2Rbeta to the SD region of the receptor, which is immediately downstream of IL-2Rbeta261-263A and overlaps with IL-2Rbeta270A 271-272R and IL-2Rbeta278-280A(12) . We have co-expressed IL-2Rbeta mutants with JAK1 in both COS-7 and CV-1 cells and have been unable to map the JAK1 binding site to any one domain of the receptor chain, including the SD region. (^4)It is of interest that JAK3, which is generally thought of as a (c)-associated molecule, fails to be activated in the context of IL-2Rbeta mutations. This finding strongly argues for cross-talk between the IL-2Rbeta and (c) through the two associated JAK kinases. Alternatively, we and others have detected an association between IL-2Rbeta and JAK3 in overexpression systems (13) .^4 This association may simply be the result of an intrinsic affinity of the JAK1 binding site for all kinases within the JAK family, and may be enhanced by the concomitant overexpression of both the receptor chain (containing the JAK1 binding site) and a JAK kinase. This result may suggest a more complex kinase activation mechanism in which (c) donates JAK3 to the IL-2Rbeta chain following ligand-induced heterodimerization of IL-2Rbeta and (c). This event might in turn permit the simultaneous activation of the JAK1 and JAK3 kinases.

In summary, these studies suggest that the IL-2Rbeta V-box region contains determinants that are critical for a very proximal step in the growth signaling cascade initiated by the IL-2R complex. Our findings further support the hypothesis that variable, rather than conserved amino acids, are essential for this process. Although this result is at first surprising, it provides an explanation for specificity of signaling by various cytokine superfamily members. The conserved residues may provide a secondary or tertiary structural motif that permits the variable residues to be exposed; these variable residues may in turn contact signaling intermediates in a very specific manner. In this way, each cytokine receptor could contact specific signaling intermediates despite common motifs. Further analyses of other cytokine receptor superfamily members will be needed to test the generality of this hypothesis.


FOOTNOTES

*
This work was supported by the J. David Gladstone Institutes. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
Participants in the National Institutes of Health Medical Scientist Training Program at the University of California, San Francisco.

To whom correspondence should be addressed: Gladstone Institute of Virology and Immunology, P. O. Box 419100, San Francisco, CA 94141. Tel.: 415-695-3800; Fax: 415-826-1817.

(^1)
The abbreviations used are: IL-2R, interleukin-2 receptor; IL-2, interleukin-2; V-box, variable box; JAK, Janus kinase; STAT factor, signal transducer and activator of transcription factor; PAGE, polyacrylamide gel electrophoresis; EMSA, electrophoretic mobility shift assay.

(^2)
S. Y. Lai, W. Xu, S. L. Gaffen, K. D. Liu, G. D. Longmore, W. C. Greene, and M. A. Goldsmith, submitted for publication.

(^3)
S. Gaffen, S. Y. Lai, M. A. Goldsmith, and W. C. Greene, unpublished observations.

(^4)
K. D. Liu, W. Xu, M. A. Goldsmith, and W. C. Greene, unpublished observations.


ACKNOWLEDGEMENTS

We thank Drs. M. Feinberg and T. Taniguchi for kindly providing cDNA and expression vectors, and Dr. B. Groner for the STAT5 antiserum. We appreciate the insightful comments of Dr. S. Gaffen. The authors acknowledge the excellent assistance of Mark Dettle, Michael Ceniceros, and John Carroll in the preparation of this manuscript.


REFERENCES

  1. Goldsmith, M. A., Xu, W., Amaral, M. C., Kuczek, E. S., and Greene, W. C. (1994) J. Biol. Chem. 269,14698-14704 [Abstract/Free Full Text]
  2. Smith, K. A. (1992) Curr. Opin. Immunol. 4,271-276 [CrossRef][Medline] [Order article via Infotrieve]
  3. Lowenthal, J. W., and Greene, W. C. (1987) J. Exp. Med. 166,1156-1161 [Abstract]
  4. Wang, H. M., and Smith, K. A. (1987) J. Exp. Med. 166,1055-1069 [Abstract]
  5. Leonard, W. J., Depper, J. M., Kanehisa, M., Kronke, M., Peffer, N. J., Svetlik, P. B., Sullivan, M., and Greene, W. C. (1985) Science 230,633-639 [Medline] [Order article via Infotrieve]
  6. Nikaido, T., Shimizu, A., Ishida, N., Sabe, H., Teshigawara, K., Maeda, M., Uchiyama, T., Yodoi, J., and Honjo, T. (1984) Nature 311,631-635 [Medline] [Order article via Infotrieve]
  7. Cosman, D., Cerretti, D. P., Larsen, A., Park, L., March, C., Dower, S., Gillis, S., and Urdal, D. (1984) Nature 312,768-771 [Medline] [Order article via Infotrieve]
  8. Nakamura, Y., Russell, S. M., Mess, S. A., Friedmann, M., Erdos, M., Francois, C., Jacques, Y., Adelstein, S., and Leonard, W. J. (1994) Nature 369,330-333 [CrossRef][Medline] [Order article via Infotrieve]
  9. Nelson, B. H., Lord, J. D., and Greenberg, P. D. (1994) Nature 369,333-336 [CrossRef][Medline] [Order article via Infotrieve]
  10. Taniguchi, T. (1995) Science 268,251-255 [Medline] [Order article via Infotrieve]
  11. Boussiotis, V. A., Barber, D. L., Nakarai, T., Freeman, G. J., Gribben, J. G., Bernstein, G. M., D'Andrea, A. D., Ritz, J., and Nadler, L. M. (1994) Science 266,1039-1042 [Medline] [Order article via Infotrieve]
  12. Miyazaki, T., Kawahara, A., Fujii, H., Nakagawa, Y., Minami, Y., Liu, Z.-J., Oishi, I., Silvennoinen, O., Witthuhn, B. A., Ihle, J. N., and Taniguchi, T. (1994) Science 266,1045-1047 [Medline] [Order article via Infotrieve]
  13. Russell, S. M., Johnston, J. A., Noguchi, M., Kawamura, M., Bacon, C. M., Friedmann, M., Berg, M., McVicar, D. W., Witthuhn, B. A., Silvennoinen, O., Goldman, A. S., Schmalstieg, F. C., Ihle, J. N., O'Shea, J. J., and Leonard, W. J. (1994) Science 266,1042-1045 [Medline] [Order article via Infotrieve]
  14. Darnell, J. E., Kerr, I. M., and Stark, G. R. (1994) Science 264,1415-1421 [Medline] [Order article via Infotrieve]
  15. Hou, J., Schindler, U., Henzel, W. J., Wong, S. C., and McKnight, S. L. (1995) Immunity 2,321-329 [Medline] [Order article via Infotrieve]
  16. Lin, J.-X., Migone, T.-S., Tsang, M., Friedmann, M., Weatherbee, J. A., Zhou, L., Yamauchi, A., Bloom, E. T., Mietz, J., John, S., and Leonard, W. J. (1995) Immunity 2,331-339 [Medline] [Order article via Infotrieve]
  17. Gaffen, S. L., Lai, S. Y., Xu, W., Gouilleux, F., Groner, B., Goldsmith, M. A., and Greene, W. C. (1995) Proc. Natl. Acad. Sci. U. S. A. 92,7192-7196 [Abstract]
  18. Beadling, C., Guschin, D., Witthuhn, B. A., Ziemiecki, A., Ihle, J. N., Kerr, I. M., and Cantrell, D. A. (1994) EMBO J. 13,5605-5615 [Abstract]
  19. Bazan, J.-F. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,6934-8 [Abstract]
  20. Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa, K., Hamaguchi, M., Taga, T., and Kishimoto, T. (1991) Proc. Natl. Acad. Sci. U. S. A. 88,11349-11353 [Abstract]
  21. Hatakeyama, M., Mori, H., Doi, T., and Taniguchi, T. (1989) Cell 59,837-845 [Medline] [Order article via Infotrieve]
  22. Goldsmith, M. A., Lai, S. Y., Xu, W., Amaral, M. C., Kuczek, E. S., Parent, L. J., Mills, G. B., Tarr, K. L., Longmore, G. D., and Greene, W. C. (1995) J. Biol. Chem. 270,21729-21737 [Abstract/Free Full Text]
  23. Mori, H., Barsoumian, E. L., Hatakeyama, M., and Taniguchi, T. (1991) Int. Immunol. 3,149-56 [Abstract]
  24. Palacios, R., and Steinmetz, M. (1985) Cell 41,727-734 [Medline] [Order article via Infotrieve]
  25. Goldsmith, M. A., Amaral, M. C., and Greene, W. C. (1995) J. Immunol. 154,2033-2040 [Abstract/Free Full Text]
  26. Schreiber, E., Matthias, P., Muller, M. M., and Schaffner, W. (1989) Nucleic Acids Res. 17,6419 [Medline] [Order article via Infotrieve]
  27. Sharon, M., Gnarra, J. R., and Leonard, W. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87,4869-4873 [Abstract]
  28. Mills, G. B., May, C., McGill, M., Fung, M., Baker, M., Sutherland, R., and Greene, W. C. (1990) J. Biol. Chem. 265,3561-3567 [Abstract/Free Full Text]
  29. Asao, H., Takeshita, T., Nakamura, M., Nagata, K., and Sugamura, K. (1990) J. Exp. Med. 171,637-644 [Abstract]
  30. Shackelford, D. A., and Trowbridge, I. S. (1991) Cell Regul. 2,73-85 [Medline] [Order article via Infotrieve]
  31. Witthuhn, B. A., Silvennoinen, O., Miura, O., Lai, K. S., Cwik, C., Liu, E. T., and Ihle, J. N. (1994) Nature 370,153-157 [CrossRef][Medline] [Order article via Infotrieve]
  32. Johnston, J. A., Kawamura, M., Kirken, R. A., Chen, Y., Blake, T. B., Shibuya, K., Ortaldo, J. R., McVicar, D. W., and O'Shea, J. J. (1994) Nature 370,151-153 [CrossRef][Medline] [Order article via Infotrieve]
  33. Goldsmith, M. A., and Greene, W. C. (1994) Interleukin-2 and the Interleukin-2 Receptor , 2d Ed., Academic Press, Ltd., London
  34. Ihle, J. N., Quelle, F. W., and Miura, O. (1993) Semin. Immunol. 5,375-389 [CrossRef][Medline] [Order article via Infotrieve]
  35. Miura, O., Nakamura, N., Quelle, F. W., Witthuhn, B. A., Ihle, J. N., and Aoki, N. (1994) Blood 84,1501-1507 [Abstract/Free Full Text]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.